Menu Search
Equities

Larimar Therapeutics Inc

ZA71:STU

Larimar Therapeutics Inc

Actions
  • Price (EUR)6.50
  • Today's Change-0.20 / -2.99%
  • Shares traded0.00
  • 1 Year change+55.50%
  • Beta--
Data delayed at least 15 minutes, as of Apr 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

  • Revenue in USD (TTM)0.00
  • Net income in USD-36.95m
  • Incorporated2005
  • Employees42.00
  • Location
    Larimar Therapeutics IncTHREE BALA PLAZA EAST. SUITE 506BALA CYNWYD 19004United StatesUSA
  • Phone+1 (617) 622-4003
  • Fax+1 (302) 655-5049
  • Websitehttps://larimartx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.